ANAVEX LIFE SCIENCES CORP. (AVXL)
Data as of , from SEC Form 4 filings.
See up to 3 months of AVXL. The 7-day demo opens the 1M and 3M ranges and puts AVXL on your watchlist.
Start 7-day demoLatest AVXL insider trades
About ANAVEX LIFE SCIENCES CORP. (AVXL)
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
- NEW YORK, NY
- 34
- 2006
- Nasdaq
AVXL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 8 | 445,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AVXL insider transactions (Form 4)
2217 Form 4 filings on record, the earliest from Dec 6, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Claus Vander Velden - Director | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Peter D.O. Donhauser - Director | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Terrie Kellmeyer - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| Axel Paeger - Director | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Christopher U. Missling - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 footnote F1 | $0.00 | - | |
| ||||||
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 12,500 footnote F1 | $0.00 | - | |
| ||||||
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 12,500 footnote F1 | $0.00 | - | |
| ||||||
| Christopher U. Missling - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 footnote F1 | $0.00 | - | |
| ||||||
| Christopher U. Missling - Officer | Option exercise | Common Stock | 187,500 | $5.04 | $945K | |
| Christopher U. Missling - Officer | Tax withholding / forfeiture | Common Stock | 145,048 | $9.58 | $1.39M | |
| Christopher U. Missling - Officer | Option exercise | Stock Option (Right to Buy) | 187,500 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
| Christopher U. Missling - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Christopher U. Missling - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
| Christopher U. Missling - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Sandra Boenisch - Officer | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Christopher U. Missling - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
AVXL insider trading FAQ
What is the latest insider trade for AVXL?
ANAVEX LIFE SCIENCES CORP. (AVXL) had 5 insider filings in the last 90 days, with the most recent on 7 November 2026. The full record for AVXL runs to 17 Form 4 filings, the earliest from 6 December 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AVXL stock?
No insider purchases of AVXL were filed in the last 90 days.
How many insiders are selling AVXL stock?
No insider sales of AVXL were filed in the last 90 days.
Where can I see AVXL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AVXL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Claus Vander Velden view on EDGAR
- - Peter D.O. Donhauser view on EDGAR
- - Terrie Kellmeyer view on EDGAR
- - Axel Paeger view on EDGAR
- - Sandra Boenisch view on EDGAR
- - Christopher U. Missling view on EDGAR
- - Sandra Boenisch view on EDGAR
- - Sandra Boenisch view on EDGAR
- - Christopher U. Missling view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where AVXL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AVXL with a 7-day demo
- AVXL on your watchlist
- Every AVXL Form 4 filing on record
- Up to 3 months of AVXL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive